Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Qiagen
NYSE:QGEN Community
1
Narratives
written by author
0
Comments
on narratives written by author
6
Fair Values set
on narratives written by author
Create a narrative
Qiagen
Popular
Undervalued
Overvalued
Qiagen
WA
Analyst Price Target
Consensus Narrative from 16 Analysts
Launches Of QIAstat Rise And QIAcuity Diagnostic Will Broaden Future Applications In Oncology And Infectious Diseases
Key Takeaways Expansion of QIAstat platform and new FDA clearances aim to boost revenue with U.S. launch of QIAstat Rise for high-throughput applications. Enhancements in digital PCR and automated sample preparation systems target growth in oncology, infectious diseases, and liquid biopsy markets.
View narrative
US$49.70
FV
19.9% undervalued
intrinsic discount
6.25%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
8 days ago
author updated this narrative
Your Valuation for
QGEN
Qiagen
Your Fair Value
US$
Current Price
US$39.82
17.2% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-41m
3b
2015
2018
2021
2024
2025
2027
2030
Revenue US$2.7b
Earnings US$116.1m
Advanced
Set as Fair Value